Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;63(6):308-316.
doi: 10.1002/em.22505. Epub 2022 Aug 30.

A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies

Changxia Shao  1 , Jun Wan  2 , Fred C Lam  3 , Huilin Tang  4 , Andrew R Marley  5 , Yiqing Song  5 , Chelsey Miller  5 , Madeline Brown  5 , Jiali Han  4 , Gboyega Adeboyeje  1
Affiliations
Review

A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies

Changxia Shao et al. Environ Mol Mutagen. 2022 Jul.

Abstract

There is significant improvement in the outcomes following treatment with PARP inhibitors among patients with certain tumors that have BRCA mutations (BRCAm), homologous recombination repair (HRR) gene mutations, or homologous recombination deficiency (HRD) positivity. We performed a literature review and meta-analysis to evaluate the prevalence of BRCA1/2m, HRR gene mutations, and HRD positivity across multiple cancers. There were 265 publications on BRCA1/2 mutation prevalence, 189 on HRR gene mutation prevalence, and 7 on HRD positivity prevalence. The prevalences of germline BRCA1m and BRCA2m were 7.8% and 5.7% for breast cancer, 13.5% and 6.6% for ovarian cancer, 0.5% and 3.5% for prostate cancer, and 1.1% and 4.1% for pancreatic cancer, respectively. The prevalences of somatic BRCA1m and BRCA2m were 3.4% and 2.7% for breast cancer, 4.7% and 2.9% for ovarian cancer, 5.7% and 3.2% for prostate cancer, and 1.2% and 2.9% for pancreatic cancer, respectively. We identified 189 studies with over 418,649 samples across 25 tumor types that examined mutations in one or more HRR genes other than BRCA1/2. The prevalence of mutations among HRR genes remained low (less than 1%), with ATM (5.2%), CHEK2 (1.6%), and PALB2 (0.9%) exhibiting the highest prevalence. Seven studies evaluated HRD positivity in breast, ovarian, and prostate cancer patients. The prevalence of HRD positivity was 56% overall (95% CI = 48%-64%). The understanding of biomarker prevalence across tumor types and standardization of biomarker assays could have important clinical implications.

Keywords: BRCA; cancer; homologous recombination deficiencies; homologous recombination gene; mutations.

PubMed Disclaimer

References

REFERENCES

    1. Byers, L.A., Wang, J., Nilsson, M.B., Fujimoto, J., Saintigny, P., Yordy, J. et al. (2012) Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discovery, 2(9), 798-811.
    1. Ford, D., Easton, D.F., Bishop, D.T., Narod, S.A. & Goldgar, D.E. (1994) Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet, 343(8899), 692-695.
    1. Futreal, P.A., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshman, K., Tavtigian, S. et al. (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science, 266(5182), 120-122.
    1. Heeke, A.L., Pishvaian, M.J., Lynce, F., Xiu, J., Brody, J.R., Chen, W.J. et al. (2018) Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precision Oncology, 2018, PO.17.00286.
    1. Helleday, T. (2011) The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Molecular Oncology, 5(4), 387-393.